Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13632434 | 0.90 | KCNA5 (0.35) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| SCHEMBL26013540 | 0.89 | BDKRB2 (0.33) | CYP2D6TLR8TLR7 | |
| SCHEMBL12464828 | 0.87 | TSHR (0.34) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| SCHEMBL26546032 | 0.86 | NR1I2 (0.41) | KCNH2 | |
| SCHEMBL25017993 | 0.82 | BDKRB2 (0.34) | KCNA5KCNH2CYP2D6TLR8TLR7 | |
| SCHEMBL13259739 | 0.79 | ESR1 (0.30) | ESR1ESR2 | |
| SCHEMBL23709479 | 0.79 | BDKRB2 (0.35) | KCNA5KCNH2CYP2D6TLR8TLR7 | |
| SCHEMBL12293361 | 0.79 | HDAC8 (0.31) | TSHR | |
| SCHEMBL26078434 | 0.79 | LMNA (0.36) | KCNH2 | |
| SCHEMBL21715637 | 0.77 | OPRM1 (0.34) | CYP2D6TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230339907-A1 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-3689876-A1 | PDE9 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| CN-1039645-C | 1,3-(substd. thio) acetoxy Melbamycinum derivatives, their preparation method, and use in agricultural chemistry | SANKYO CO (JP) | 1998-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | KCNA5 3193/4885KCNH2 3883/4885CYP2D6 229/4885 |
| US-20230339907-A1 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | DHPS, PDXK, NQO1 | KCNA5 257/4885KCNH2 348/4885CYP2D6 72/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | KCNA5 4213/4885KCNH2 4512/4885CYP2D6 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.